Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- IMVT
- Price
- 26.28
- Stock movement up
- +0.53 (2.06%)
- Company name
- Immunovant Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 5.35B
- Ent value
- 4.42B
- Price/Sales
- 33430.16
- Price/Book
- 5.42
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 12.18%
- 1 year return (CAGR)
- 32.33%
- 3 year return (CAGR)
- 12.27%
- 5 year return (CAGR)
- 1.41%
- 10 year return (CAGR)
- -
Last updated: 2026-02-19
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
IMVT does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 33430.16 |
| Price to Book | 5.42 |
| EV to Sales | 27628.49 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 203.53M |
| EPS (TTM) | -2.56 |
| FCF per share (TTM) | -2.33 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 160.00K |
| Gross profit (TTM) | -233.00K |
| Operating income (TTM) | -487.17M |
| Net income (TTM) | -464.20M |
| EPS (TTM) | -2.56 |
| EPS (1y forward) | -2.67 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -145.63% |
| Operating margin (TTM) | -214748.36% |
| Profit margin (TTM) | -214748.36% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 994.52M |
| Net receivables | 1.64M |
| Total current assets | 1.04B |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 1.05B |
| Accounts payable | 8.62M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 66.26M |
| Total liabilities | 66.26M |
| Shareholder's equity | 986.13M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -422.89M |
| Capital expenditures (TTM) | 201.00K |
| Free cash flow (TTM) | -423.09M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -47.07% |
| Return on Assets | -44.11% |
| Return on Invested Capital | -47.07% |
| Cash Return on Invested Capital | -42.90% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 25.91 |
| Daily high | 26.63 |
| Daily low | 25.72 |
| Daily Volume | 1.18M |
| All-time high | 52.71 |
| 1y analyst estimate | 40.63 |
| Beta | 0.62 |
| EPS (TTM) | -2.56 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 18 Feb 2026 |
Downside potential
Loading...
Downside potential data
| IMVT | S&P500 | |
| Current price drop from All-time high | -50.14% | -1.82% |
| Highest price drop | -93.59% | -56.47% |
| Date of highest drop | 16 Jun 2022 | 9 Mar 2009 |
| Avg drop from high | -51.44% | -10.84% |
| Avg time to new high | 22 days | 12 days |
| Max time to new high | 1317 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
5.35B
Marketcap category
Mid-cap
Description
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Employees
362
Website
Investor relations
-
SEC filings
CEO
Peter Salzmann
Country
USA
City
New York
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page